2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12C.08 Surufatinib Plus Docetaxel in Patients with Relapsed Advanced Driver-Negative Non-Squamous NSCLC: A Phase Ib/II Study

P3.12C.08 Surufatinib Plus Docetaxel in Patients with Relapsed Advanced Driver-Negative Non-Squamous NSCLC: A Phase Ib/II Study

Back to course

Pdf Summary

The study explores the efficacy and safety of combining surufatinib, a small-molecule inhibitor, with docetaxel as a treatment for patients with recurrent advanced driver-negative non-squamous non-small cell lung cancer (nsq-NSCLC) after first-line therapy failure. Surufatinib targets VEGFR1-3, FGFR1, and CSF-1R and showed promising synergistic effects with chemotherapy in preclinical models.<br /><br />This Phase Ib/II study enrolled 19 patients, assessing the outcomes in terms of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and safety. The results demonstrated a 31.25% ORR among 16 evaluable patients with a complete DCR. Notably, patients without extrapulmonary metastases showed a higher ORR (57.14%) compared to those with such metastases (11.11%). Additionally, a median PFS of 5.4 months was observed. The median overall survival (OS) has not been reached yet, indicating potentially favorable outcomes.<br /><br />Regarding safety, all patients experienced at least one treatment-emergent adverse event (TEAE), with leukopenia, neutropenia, and increased aspartate aminotransferase being the most common. Dose-limiting toxicities were identified, leading to an established recommended phase 2 dose (RP2D) for surufatinib as 200mg.<br /><br />The study concludes that the combination of surufatinib and docetaxel achieves notable survival benefits and anti-tumor activity with manageable toxicities, particularly in patients without extrapulmonary metastases. These findings suggest that this combination therapy could be efficacious for a broader cohort of NSCLC patients. Further investigation in larger clinical trials is warranted to substantiate these results. Overall, this combined therapy represents a potential new avenue for treatment in a difficult-to-treat population lacking driver gene mutations.

Asset Subtitle

Qi Tao Yu

Meta Tag

Speaker Qi Tao Yu

Topic Metastatic NSCLC – Targeted Therapy

Keywords

surufatinib

docetaxel

non-small cell lung cancer

NSCLC

VEGFR

FGFR

CSF-1R

objective response rate

progression-free survival

treatment-emergent adverse events